Skip to main content
SpringerLink
Log in

Van ambachtsman tot systeembeheerder. Wat is er met de psychiater gebeurd?

  • Chapter
  • First Online:
Wat is er met de dokter gebeurd?

  • 712 Accesses

Samenvatting

Dit hoofdstuk beschrijft ongewenste ontwikkelingen in de ggz, opgetreden als ongepland gevolg van een onvoorziene systeemdynamiek die zich ontrolde sinds de introductie van marktwerking in de zorg. Daarnaast wordt onderzocht waarom veel psychiaters en andere behandelaars daar de afgelopen jaren onbedoeld enthousiast aan hebben meegewerkt. De patiënt is de dupe.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 49.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatuur

  1. Arciniegas DB, Kaufer DI. Core curriculum for training in behavioral neurology and neuropsychiatry. J Neuropsychiatry Clin Neurosci. 2006;18(1):6–13.

    Article  PubMed  Google Scholar 

  2. Os J van. De DSM-5 voorbij! Persoonlijke diagnostiek in een nieuwe ggz. Leusden: Diagnosis; 2015.

    Google Scholar 

  3. Koekoek B. Verward in Nederland. Hoe we omgaan met mensen met psychische stoornissen. Lannoo: Tielt; 2016.

    Google Scholar 

  4. Os J van, Kahn R, Denys D, Schoevers RA, Beekmann AT, et al. ROM: Gedragsnorm of dwangmaatregel? Tijdschr Psychiatr. 2012;54(3):245–53.

    Google Scholar 

  5. Beurs E de, Emmelkamp P. Routine outcome monitoring. In: Emmelkamp P, Hoogduin K, redactie. Van mislukking naar succes in de psychotherapie. Amsterdam: Boom; 2013. pag. 69–92.

    Google Scholar 

  6. Bos R ten. Bureaucratie is een inktvis. Amsterdam: Boom; 2015.

    Google Scholar 

  7. Bouvy PF. Schizofrenie bestaat wel/niet/weet niet. Tijdschr Psychiatr. 2016;58(7):513–9.

    PubMed  CAS  Google Scholar 

  8. Research Domain Criteria (RDoC). National Institute of Mental Health. Beschikbaar via: nimh.nih.gov/research-priorities/rdoc/index.shtml. Geraadpleegd op 11 april 2018.

  9. Whitaker R. Anatomy of an epidemic. New York: Crown; 2010.

    Google Scholar 

  10. Arts K. Stoornissen door een somatische aandoening in de DSM-5, leerzaam verwarrend. In: Ingenhoven TJM, redactie. De DSM-5 welbeschouwd. Nederlandse experts aan het woord. Utrecht: De Tijdstroom; 2017.

    Google Scholar 

  11. Kim JS, Lee EJ, Park JH, Ahn SH, Cha JK, Heo JH, et al. Efficacy of early administration of escitalopram on depressive and emotional symptoms and neurological dysfunction after stroke: a multicentre, double-blind, randomised, placebo-controlled study. Lancet Psychiatry. 2017;4(1):33–41.

    Article  PubMed  Google Scholar 

  12. Hasselmann HWW. Ketamine as antidepressant? Current state and future perspectives. Curr Neuropharmacol. 2014;12(1):57–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wampold BE, Imel ZE. The great psychotherapy debate. The evidence for what makes psychotherapy work. 2nd edition. New York: Routledge; 2015.

    Google Scholar 

  14. Gøtzsche PC. Deadly psychiatry and organized denial. København: People’s Press; 2015.

    Google Scholar 

  15. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45.

    Google Scholar 

  16. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, Fawcett J. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression. Cochrane Database Syst Rev. 2004;(1):CD003012.

    Google Scholar 

  18. Melander H, Salmonson T, Abadie E, van Zwieten-Boot B. A regulatory Apologia – a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol. 2008;18(9):623–7.

    Google Scholar 

  19. Gibbons RD, Hur K, Brown CH, Davis JM, Mann JJ. Benefits from antidepressants: synthesis of 6-week patient-level outcomes from double-blind placebo-controlled randomized trials of fluoxetine and venlafaxine. Arch Gen Psychiatry. 2012;69(6):572–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Kirsch I. The emperor’s new drugs: exploding the antidepressant myth. New York: Basic Books; 2011.

    Google Scholar 

  21. Vinkers C, Vis R. Even slikken. De zin en onzin van antidepressiva. Amsterdam: Prometheus; 2017.

    Google Scholar 

  22. Hasler G. Pathophysiology of depression: do we have any solid evidence of interest to clinicians? World Psychiatry. 2010;9(3):155–61.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Lawrie SM, Olabi B, Hall J, McIntosh AM. Do we have any solid evidence of clinical utility about the pathophysiology of schizophrenia? World Psychiatry. 2011;10(1):19–31.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Luyendijk J. Dit kan niet waar zijn; Onder bankiers. Amsterdam: Atlas Contact; 2015.

    Google Scholar 

  25. Varoufakis Y. Adults in the room; My battle with the European and American deep establishment. New York: Farrar, Strauss and Giroux; 2017.

    Google Scholar 

  26. Jaspers K. Allgemeine Psychopathologie. Berlijn: Springer; 1913, 1920, 1923, 1946.

    Google Scholar 

  27. Moncrieff J. The myth of the chemical cure; A critique of psychiatric drug treatment. Revised edition. London: Palgrave Macmillan; 2009.

    Google Scholar 

  28. Ernst E. Placebo: new insights into an old enigma. Drug Discov Today. 2007;12(9–10):413–8.

    Article  PubMed  Google Scholar 

  29. Benedetti F. Placebo effects: from the neurobiological paradigm to translational implications. Neuron. 2014;84(3):623–37.

    Article  CAS  PubMed  Google Scholar 

  30. Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA. 1992;268(17):2420–5.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Thalamus, Pro Persona, Wolfheze, Topklinisch Centrum voor Korsakov en Alcoholgerelateerde Stoornissen en Topklinisch Centrum voor Neuropsychiatrie, Vincent van Gogh Instituut, Venray, Nederland

    Drs. N. J. M. Arts (Gedragsneuroloog)

Authors
  1. Drs. N. J. M. Arts
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Afdeling Neurologie, Radboud Universitair Medisch Centrum, Nijmegen, The Netherlands

    Baziel van Engelen

  2. Radboud UMC, Nijmegen, The Netherlands

    Gert Jan van der Wilt

  3. University College London Hospitals, London, UK

    Marcel Levi

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Bohn Stafleu van Loghum is een imprint van Springer Media B.V., onderdeel van Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Arts, N.J.M. (2018). Van ambachtsman tot systeembeheerder. Wat is er met de psychiater gebeurd?. In: van Engelen, B., van der Wilt, G., Levi, M. (eds) Wat is er met de dokter gebeurd?. Bohn Stafleu van Loghum, Houten. https://doi.org/10.1007/978-90-368-2153-7_6

Download citation

  • DOI: https://doi.org/10.1007/978-90-368-2153-7_6

  • Published:

  • Publisher Name: Bohn Stafleu van Loghum, Houten

  • Print ISBN: 978-90-368-2152-0

  • Online ISBN: 978-90-368-2153-7

  • eBook Packages: Dutch language eBook collection

Publish with us

Policies and ethics

Search

Navigation